Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity

References

• Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. doi:10.1056/NEJMoa043330.
   PubMed Web of Science ®Google Scholar
• Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488:522–526. doi:10.1038/nature11287.
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760. doi:10.1038/nature05236.
   PubMed Web of Science ®Google Scholar
• Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006;13:1238–1241. doi:10.1038/sj.cdd.4401872.
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, Grotenhuis JA, Hoogerbrugge PM, De Vries IJM, Adema GJ. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2009;11:394–402. doi:10.1215/15228517-2008-104.
   PubMed Web of Science ®Google Scholar
• Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016:1.
   Web of Science ®Google Scholar
• Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 2010;9:67–78. doi:10.1158/1535-7163.MCT-09-0734.
   PubMed Web of Science ®Google Scholar
• Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 1999;100:216–232. doi:10.1016/S0165-5728(99)00203-9.
   PubMed Web of Science ®Google Scholar
• Ashkenazi E, Deutsch M, Tirosh R, Weinreb A, Tsukerman A, Brodie C. A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: increased level of soluble IL-2R and reduced protein tyrosine phosphorylation. Neuroimmunomodulation. 1997;4:49–56. doi:10.1159/000097315.
   PubMed Web of Science ®Google Scholar
• Reinhard J, Brosicke N, Theocharidis U, Faissner A. The extracellular matrix niche microenvironment of neural and cancer stem cells in the brain. Int J Biochem Cell Biol. 2016;81:174–183. doi:10.1016/j.biocel.2016.05.002.
   PubMed Web of Science ®Google Scholar
• Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol. 2004;36:1046–1069. doi:10.1016/j.biocel.2004.01.013.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mirzaei R, Zemp FJ, Wei W, Senger DL, Robbins SM, Yong VW. Activation of NOTCH signaling by tenascin-C promotes growth of human brain tumor-initiating cells. Cancer Res. 2017;77:3231–3243. doi:10.1158/0008-5472.CAN-16-2171.
   PubMed Web of Science ®Google Scholar
• Brosicke N, Van Landeghem FK, Scheffler B, Faissner A. Tenascin-C is expressed by human glioma in vivo and shows a strong association with tumor blood vessels. Cell Tissue Res. 2013;354:409–430. doi:10.1007/s00441-013-1704-9.
   PubMed Web of Science ®Google Scholar
• Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer. 2002;98:362–369. doi:10.1002/ijc.10233.
   PubMed Web of Science ®Google Scholar
• Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer. 2003;98:2430–2439. doi:10.1002/(ISSN)1097-0142.
   PubMed Web of Science ®Google Scholar
• Garikapati KR, Patel N, Makani VK, Cilamkoti P, Bhadra U, Bhadra MP. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/beta-catenin signaling pathway. Biochem Biophys Res Commun. 2017;484:93–99. doi:10.1016/j.bbrc.2017.01.066.
   PubMed Web of Science ®Google Scholar
• Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massagué J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17:867–874. doi:10.1038/nm.2379.
   PubMed Web of Science ®Google Scholar
• Hibino S, Kato K, Kudoh S, Yagita H, Okumura K. Tenascin suppresses CD3-mediated T cell activation. Biochem Biophys Res Commun. 1998;250:119–124. doi:10.1006/bbrc.1998.9258.
   PubMed Web of Science ®Google Scholar
• Puente Navazo MD, Valmori D, Ruegg C. The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production. J Immunol (Baltimore, Md: 1950). 2001;167:6431–6440. doi:10.4049/jimmunol.167.11.6431.
   PubMed Web of Science ®Google Scholar
• Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M, Piras IS, Restuccia U, Calcinotto A, Freschi M, et al. Tenascin-C protects cancer stem-like cells from immune surveillance by arresting T-cell activation. Cancer Res. 2015;75:2095–2108. doi:10.1158/0008-5472.CAN-14-2346.
   PubMed Web of Science ®Google Scholar
• Huang JY, Cheng YJ, Lin YP, Lin HC, Su CC, Juliano R, Yang B-C. Extracellular matrix of glioblastoma inhibits polarization and transmigration of T cells: the role of tenascin-C in immune suppression. J Immunol (Baltimore, Md: 1950). 2010;185:1450–1459. doi:10.4049/jimmunol.0901352.
   PubMed Web of Science ®Google Scholar
• Didem T, Faruk T, Senem K, Derya D, Murat S, Murat G, Oznur K. Clinical significance of serum tenascin-c levels in epithelial ovarian cancer. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35:6777–6782. doi:10.1007/s13277-014-1923-z.
   PubMed Web of Science ®Google Scholar
• Riedl S, Bodenmuller H, Hinz U, Holle R, Moller P, Schlag P, Herfarth C, Faissner A. Significance of tenascin serum level as tumor marker in primary colorectal carcinoma. Int J Cancer. 1995;64:65–69. doi:10.1002/(ISSN)1097-0215.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv Exp Med Biol. 2002;513:397–430.
   PubMed Web of Science ®Google Scholar
• Erickson HP, Bourdon MA. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol. 1989;5:71–92. doi:10.1146/annurev.cb.05.110189.000443.
   PubMedGoogle Scholar
• Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30:836–848. doi:10.1016/j.ccell.2016.10.009.
   PubMed Web of Science ®Google Scholar
• Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O’Connor S, Chin A, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25:501–515. doi:10.1016/j.ccr.2014.03.007.
   PubMed Web of Science ®Google Scholar
• Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, Lötvall J, Nakagama H, Ochiya T. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015;6:6716. doi:10.1038/ncomms7716.
   PubMed Web of Science ®Google Scholar
• Domenis R, Cesselli D, Toffoletto B, Bourkoula E, Caponnetto F, Manini I, Beltrami AP, Ius T, Skrap M, Di Loreto C, et al. Systemic T cells immunosuppression of glioma stem cell-derived exosomes is mediated by monocytic myeloid-derived suppressor cells. PLoS One. 2017;12:e0169932. doi:10.1371/journal.pone.0169932.
   PubMed Web of Science ®Google Scholar
• Skog J, Wurdinger T, Van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–1476. doi:10.1038/ncb1800.
   PubMed Web of Science ®Google Scholar
• Pisklakova A, McKenzie B, Zemp F, Lun X, Kenchappa RS, Etame AB, Rahman MM, Reilly K, Pilon-Thomas S, McFadden G, et al. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma. Neuro Oncol. 2016. doi:10.1093/neuonc/now006.
   PubMedGoogle Scholar
• Kominsky S, Johnson HM, Bryan G, Tanabe T, Hobeika AC, Subramaniam PS, Torres B. IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1. Oncogene. 1998;17:2973–2979. doi:10.1038/sj.onc.1202217.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Doring A, Zemp FJ, Silva C, Lun X, Wang X, Kelly J, Hader W, Hamilton M, Mercier P, et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci. 2014;17:46–55. doi:10.1038/nn.3597.
   PubMed Web of Science ®Google Scholar
• Zou JP, Morford LA, Chougnet C, Dix AR, Brooks AG, Torres N, Shuman JD, Coligan JE, Brooks WH, Roszman TL, et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol (Baltimore, Md: 1950). 1999;162:4882–4892.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Weller M, Heimberger AB. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015;17(Suppl 7):vii9–vii14. doi:10.1093/neuonc/nov151.
   PubMed Web of Science ®Google Scholar
• Lochter A, Vaughan L, Kaplony A, Prochiantz A, Schachner M, Faissner A. J1/tenascin in substrate-bound and soluble form displays contrary effects on neurite outgrowth. J Cell Biol. 1991;113:1159–1171. doi:10.1083/jcb.113.5.1159.
   PubMed Web of Science ®Google Scholar
• Garcion E, Halilagic A, Faissner A, ffrench-Constant C. Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development. 2004;131:3423–3432. doi:10.1242/dev.01202.
   PubMed Web of Science ®Google Scholar
• Karus M, Denecke B, ffrench-Constant C, Wiese S, Faissner A. The extracellular matrix molecule tenascin C modulates expression levels and territories of key patterning genes during spinal cord astrocyte specification. Development. 2011;138:5321–5331. doi:10.1242/dev.067413.
   PubMed Web of Science ®Google Scholar
• Tucker RP, Chiquet-Ehrismann R. Tenascin-C: its functions as an integrin ligand. Int J Biochem Cell Biol. 2015;65:165–168. doi:10.1016/j.biocel.2015.06.003.
   PubMed Web of Science ®Google Scholar
• Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006. Chapter 3:Unit3.22. doi:10.1002/0471143030.cb0322s30.
   PubMedGoogle Scholar
• Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. doi:10.1038/nature03128.
   PubMed Web of Science ®Google Scholar
• Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, Li J, Zhang Y, Chen L, Qian H, et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011;11:71. doi:10.1186/1471-230X-11-71.
   PubMed Web of Science ®Google Scholar
• Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69–82. doi:10.1016/j.ccr.2006.11.020.
   PubMed Web of Science ®Google Scholar
• Faissner A, Roll L, Theocharidis U. Tenascin-C in the matrisome of neural stem and progenitor cells. Mol Cell Neurosci. 2017;81:22–31. doi:10.1016/j.mcn.2016.11.003.
   PubMed Web of Science ®Google Scholar
• Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244:143–163. doi:10.1016/j.canlet.2006.02.017.
   PubMed Web of Science ®Google Scholar
• Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5:816–826. doi:10.1038/nrm1490.
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22. doi:10.1038/nrc2748.
   PubMed Web of Science ®Google Scholar
• Paron I, Berchtold S, Voros J, Shamarla M, Erkan M, Hofler H, Esposito I, Gottardi C. Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS One. 2011;6:e21684. doi:10.1371/journal.pone.0021684.
   PubMed Web of Science ®Google Scholar
• Saci A, Cantley LC, Carpenter CL. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell. 2011;42:50–61. doi:10.1016/j.molcel.2011.03.017.
   PubMed Web of Science ®Google Scholar
• Hauzenberger D, Olivier P, Gundersen D, Ruegg C. Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1-5 repeats to fibronectin. Eur J Immunol. 1999;29:1435–1447. doi:10.1002/(SICI)1521-4141(199905)29:05<1435::AID-IMMU1435>3.0.CO;2-N.
   PubMed Web of Science ®Google Scholar
• Hellwinkel JE, Redzic JS, Harland TA, Gunaydin D, Anchordoquy TJ, Graner MW. Glioma-derived extracellular vesicles selectively suppress immune responses. Neuro Oncol. 2016;18:497–506. doi:10.1093/neuonc/nov170.
   PubMed Web of Science ®Google Scholar
• Ren Y, Yang J, Xie R, Gao L, Yang Y, Fan H, Qian K. Exosomal-like vesicles with immune-modulatory features are present in human plasma and can induce CD4+ T-cell apoptosis in vitro. Transfusion. 2011;51:1002–1011. doi:10.1111/trf.2011.51.issue-5.
   PubMed Web of Science ®Google Scholar
• Esposito I, Penzel R, Chaib-Harrireche M, Barcena U, Bergmann F, Riedl S, Kayed H, Giese N, Kleeff J, Friess H, et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol. 2006;208:673–685. doi:10.1002/(ISSN)1096-9896.
   PubMed Web of Science ®Google Scholar
• Czopka T, Von Holst A, ffrench-Constant C, Faissner A. Regulatory mechanisms that mediate tenascin C-dependent inhibition of oligodendrocyte precursor differentiation. J Neuroscience: Official Journal Soc Neurosci. 2010;30:12310–12322. doi:10.1523/JNEUROSCI.4957-09.2010.
   PubMed Web of Science ®Google Scholar
• Gotz B, Scholze A, Clement A, Joester A, Schutte K, Wigger F, Frank R, Spiess E, Ekblom P, Faissner A. Tenascin-C contains distinct adhesive, anti-adhesive, and neurite outgrowth promoting sites for neurons. J Cell Biol. 1996;132:681–699. doi:10.1083/jcb.132.4.681.
   PubMed Web of Science ®Google Scholar
• Lun X, Wells JC, Grinshtein N, King JC, Hao X, Dang NH, Wang X, Aman A, Uehling D, Datti A, et al. Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma. Clin Cancer Res. 2016;22:3860–3875. doi:10.1158/1078-0432.CCR-15-1798.
   PubMed Web of Science ®Google Scholar
• Vecil GG, Larsen PH, Corley SM, Herx LM, Besson A, Goodyer CG, Yong VW. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res. 2000;61:212–224. doi:10.1002/(ISSN)1097-4547.
   PubMed Web of Science ®Google Scholar